Sales Performance - Q3 sales increased by 14.7% to $1.55 billion, with adjusted growth of 12.6% across all product groups[4] - TAVR sales reached $1.15 billion, growing 12.4% year-over-year, or 10.6% on a constant currency basis[5] - TMTT sales were $145.2 million, representing a year-over-year growth of 59.3%[8] - Net sales for Q3 2025 reached $1,553.1 million, a 14.7% increase from $1,354.4 million in Q3 2024[31] - Year-to-date sales for 2025 totaled $4,498.0 million, reflecting an increase of $444.3 million or 11.0% compared to the same period in 2024[45] - Sales in the United States for Q3 2025 were $907.5 million, a growth of $102.9 million or 12.8% year-over-year[45] - European sales increased by 21.3% to $387.9 million, up $68.1 million from Q3 2024[45] - Outside the United States, sales reached $645.6 million, representing a growth of 17.4% compared to the previous year[45] - The company reported a 59.8% increase in Transcatheter Mitral and Tricuspid Therapies year-to-date, with sales of $394.9 million[45] - Surgical Structural Heart sales for Q3 2025 were $258.0 million, an increase of $18.0 million or 7.5% from Q3 2024[45] Financial Metrics - Adjusted EPS for Q3 was $0.67, with a reported EPS of $0.50[4] - The company raised its full-year sales growth guidance to the high end of 9-10% and adjusted EPS guidance to $2.56 to $2.62[22] - The adjusted gross profit margin for Q3 was 77.9%, down from 80.7% in the same period last year[17] - Gross profit margin for Q3 2025 was 77.8%, down from 80.6% in Q3 2024[31] - The effective tax rate for Q3 2025 was 16.1%, compared to 10.1% in Q3 2024[31] - Basic earnings per share from continuing operations for Q3 2025 was $0.50, down from $0.61 in Q3 2024[31] - The adjusted net income for the same period was $389.9 million, with an adjusted EPS of $0.67, reflecting a profit margin of 27.5%[43] - For the nine months ended September 30, 2025, net sales reached $4,498.0 million, with a gross profit margin of 78.0% and a net income of $995.9 million, leading to an EPS of $1.70[44] - The adjusted net income for the nine months was $1,160.3 million, with an adjusted EPS of $1.98, indicating a profit margin of 28.3%[44] Expenses and Costs - SG&A expenses were $515 million, or 33.1% of sales, compared to $421 million, or 31.1% of sales last year[18] - R&D expenses increased to $281 million, reflecting strategic investments in the structural heart portfolio[19] - The company recorded certain litigation expenses of $90.4 million in Q3 2025, significantly higher than $10.8 million in Q3 2024[36] - Intangible assets impairment charges amounted to $40.0 million in Q3 2025, with no such charges in Q3 2024[38] - The company incurred certain litigation expenses of $90.4 million for the three months ended September 30, 2025, impacting the net income[43] - For the nine months ended September 30, 2025, litigation expenses totaled $116.8 million, which also affected the overall financial performance[44] Future Outlook - The company plans to project total sales for Q4 between $1.51 and $1.59 billion, with adjusted EPS of $0.58 to $0.64[22] - The company plans to continue focusing on litigation management and cost control to enhance future profitability and operational efficiency[43] - The company anticipates continued growth in the Implantable Heart Failure Management segment, with adjustments starting in September 2025[45]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying EW stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Applied Therapeutics, Inc. (NASDAQ: APLT), encouraging shareholders to contact the firm to discuss their rights [1][2]. Company Summary - The investigation focuses on whether the management of Applied Therapeutics has acted in the best interests of shareholders, which may lead to corporate governance reforms and financial recoveries for investors [1][2]. - Long-term shareholders of Applied Therapeutics may seek various forms of relief, including the return of funds to the company and court-approved financial incentives [2][3]. Legal Context - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered significant amounts for defrauded investors [4].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Edwards Lifesciences Corporation, urging shareholders to contact the firm to discuss their rights [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Edwards Lifesciences may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2]. - Shareholder involvement is emphasized as a means to improve company policies and enhance shareholder value through better oversight and accountability [3]. Group 2: Firm's Background and Experience - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Insights - Edwards Lifesciences announced successful patient outcomes for its mitral and tricuspid therapies, with one-year data from the ENCIRCLE trial meeting all primary and secondary endpoints for safety and effectiveness [1] - The outcomes were published in The Lancet, highlighting the significance of the findings in the medical community [1] - Additionally, thirty-day data from the EVOQUE system STS/ACC TVT Registry was reported, which is noted as the largest real-world transcatheter tricuspid valve replacement registry [1]

Core Insights - Edwards Lifesciences announced seven-year data from the PARTNER 3 trial, highlighting early and sustained patient benefits from its TAVR technology [1] - The data demonstrated superior clinical outcomes at one year, along with excellent long-term valve performance and durability [1] - Additionally, ten-year results from PARTNER 2 intermediate risk studies further reinforce Edwards' leadership in establishing standards for lasting valve performance and patient outcomes [1]

Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW) [1] Group 1 - The investigation is focused on the actions of the company's directors and officers, suggesting possible legal implications for Edwards Lifesciences [1] - Investors who own shares of Edwards stock are encouraged to seek more information through Rosen Law Firm's website or contact details [2] - Rosen Law Firm emphasizes its experience and success in handling securities class actions, highlighting its track record and recognition in the legal field [3]

Core Insights - Edwards Lifesciences is set to announce its operating results for Q3 2025 on October 30, 2025, followed by a conference call to discuss these results [1][2]. Company Overview - Edwards Lifesciences is recognized as a leading global company in structural heart innovation, focusing on improving patient lives through advanced technologies and partnerships with healthcare stakeholders [3]. Financial Activities - The company has executed an accelerated share repurchase agreement to buy back $500 million of its common stock, bringing the total repurchased shares in 2025 to over $800 million [8]. Regulatory Developments - The U.S. Federal Trade Commission (FTC) has moved to block Edwards Lifesciences' proposed acquisition of JenaValve Technology, which the company believes will limit treatment options for patients with aortic regurgitation [9].

Core Insights - Edwards Lifesciences Corporation (NYSE:EW) is recognized as one of the top medical device stocks to invest in, with Piper Sandler maintaining an Overweight rating and a $90 price target ahead of the PARTNER 3 study findings [1][2] Group 1: Company Overview - Edwards Lifesciences Corporation specializes in developing and selling patient-focused medical innovations, including transcatheter heart valves and hemodynamic monitoring systems for treating structural heart disease and critical care [2] Group 2: PARTNER 3 Study - The PARTNER 3 trial, which has a follow-up period of ten years, compares surgical aortic valve replacement (SAVR) with the Sapien 3 transcatheter aortic valve replacement (TAVR) in low-risk patients [2] - Upcoming data from the PARTNER 3 study is expected to demonstrate that TAVR is not inferior to SAVR, which may result in findings that have minimal commercial implications [2]

Core Insights - Edwards Lifesciences Corp. (EW) is set to report its third-quarter 2025 results on October 30, after market close [1][9] - The company’s adjusted earnings per share for the last quarter were 67 cents, exceeding the Zacks Consensus Estimate by 8.06%, with an average surprise of 5.50% over the past four quarters [1] Q3 Estimates - The Zacks Consensus Estimate for revenues is $1.50 billion, indicating an 11.5% growth from the previous year [2] - The earnings estimate is 59 cents per share, reflecting an 11.9% decline from the year-ago figure [2][3] Performance Factors - The Transcatheter Aortic Valve Replacement (TAVR) segment is expected to perform strongly in the U.S., driven by the SAPIEN 3 Ultra RESILIA platform, with projected sales of $1.11 billion, an 8.5% year-over-year increase [4][5][9] - The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is anticipated to report revenues of $134.1 million, a 47.2% increase from the previous year, supported by the PASCAL repair system and the EVOQUE tricuspid replacement system [6][7][9] - The Surgical Structural Heart segment is estimated to generate revenues of $256.7 million, reflecting a 7% rise from the year-ago quarter, aided by the global adoption of the RESILIA portfolio [10] Earnings Expectations - Edwards has an Earnings ESP of +0.47%, indicating a higher likelihood of beating estimates [11] - The company currently holds a Zacks Rank of 3, suggesting a neutral outlook [12]